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Natural killer (NK) cells are an essential component of innate immunity that provides a rapid
response to detect stressed, infected, or transformed target cells.This system is controlled
by a balance of inhibitory and activating signals transmitted by a myriad of receptors and
their specific ligands. Inhibitory receptors mainly recognize self-MHC class-I molecules,
whereas activating receptors, such as natural cytotoxic receptors, NKG2D, and DNAM-1,
interact with self-proteins, normally not expressed on the cell surface of healthy cells,
but up-regulated by cellular stress or infections and are frequently expressed on tumor
cells. In these circumstances, regulatory controls ensure that specific ligands are induced
mainly in diseased cells and not in normal cells. Each ligand seems to exhibit some distinct
specializations providing broad “coverage” for numerous stresses associated with various
diseases. Deregulated cell proliferation is a hallmark of these abnormal situations, and may
serve as a sentinel for the elimination of the targets by NK cells.The purpose of this review
is to discuss recent implications of cell-cycle to create a warning control system that relays
various danger signals via specific ligands to the NK receptor system.
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INTRODUCTION
Natural killer (NK) cells are key components of the innate immune
system, known to display strong cytolytic activity against tumor-
or virus-infected cells, as well as immunoregulatory functions that
influence adaptive immune responses (1, 2). Their functions are
regulated by a series of surface receptors transducing inhibitory
or activating signals. Inhibitory receptors are mainly represented
by killer immunoglobulin-like receptors (KIRs), CD94/NKG2A,
and ILT-2; they all recognize self-molecules of the HLA class-
I repertoire, constitutively expressed on host cells. To destroy a
target, NK cells are also composed of several activating recep-
tors, like NKG2D, DNAX accessory molecule-1 (DNAM-1), an
adhesion molecule physically and functionally associated to LFA-
1 (Lymphocyte function-associated antigen 1), and the natural
cytotoxicity receptors (NCRs; NKp30, NKp44, and NKp46) (3–5).
Simultaneous interactions of certain of these activating receptors
on NK cells with their specific ligands on the target cells lead to the
integration of different intracellular signals, which together both
dictate the quality and intensity of the effector NK cell response.
The relative contribution of each of the activating receptors to
NK cytotoxicity against target cells differs, indicating the exis-
tence of specific ligands. Indeed, multiple stress inducible cellular
proteins have been identified. The NKG2D ligands comprise the
MHC class-I chain related antigens (MIC-A and MIC-B) and
the UL16 binding proteins (ULBP-1-6) (5), whereas, DNAM-1
recognizes the poliovirus receptor (PVR) and Nectin-2 (6). The
identity of ligands for NCRs is a field of intense investigations;
nuclear leukocyte antigen-B-associated transcript 3 (BAT3) fac-
tor, which is released from tumor cells under stress conditions,
and a member of the B7 family, B7-H6, only expressed on tumor
cells, both have been identified as cellular ligands for NKp30
(7, 8). Concomitantly, we have recently identified a cellular lig-
and of NKp44, called NKp44L, which is a novel isoform of the
mixed-lineage leukemia-5 (MLL5) protein, expressed on a large
panel of the tumor and transformed cells, and induced during
Human immunodeficiency virus 1 (HIV-1) infection (9,10). These
virus-, stress-, or transformation-inducible ligands are normally
not expressed on the cell surface of cells from healthy individuals,
although in certain conditions high level of ligands can be found
in healthy cells, such PVR on vascular endothelial cells (11), or
NKp44L on articular chondrocytes (12). This suggests however,
that small changes in their cell-surface profile may significantly
influence the susceptibility of these targets to the NK cells. This is
consistent with the idea that their expression needs to be regulated
at different levels, including epigenetic, transcriptional, and post-
transcriptional mechanisms. These levels of regulation may serve
as serial checkpoints to ensure that ligands are induced only in
diseased cells and not in normal cells. To date, however, this phe-
nomenon is only partially understood. Recent insights in this field
suggest that cell-cycle progression could be used as an endogenous
indicator for potential danger for limiting tumor growth and viral
replication. The cell-cycle machinery is distinguished by a series
of coordinated events essential to ensure faithful DNA replica-
tion and segregation of replicated chromosomes into two separate
cells. Replication of DNA occurs during the S phase. The S phase
is preceded by the G1 phase during which the cell is preparing
for DNA synthesis. The active replication of the chromosomes
occurs during the S phase. Subsequently, the cells enter a further
G2 gap period, prior to chromosome segregation and cytokine-
sis in M phase (mitosis), followed by an immediate re-entry into
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FIGURE 1 | Schematic representation of the interactions between the
control of the cell cycle and the expression of specific ligands for
activating NK receptors in various pathologies. Cell-cycle actors are in
squares and DNA damage pathway in triangles. The modulation of activating
NK ligands expression in cancers or viral infections is indicated in gray. CDK,
cyclin-dependent kinase; Rb, retinoblastoma tumor suppressor gene; ATM,
ataxia-telangiectasia-mutated; ATR, ataxia, and rad3 related; PCNA,
proliferating cell nuclear antigens.
G1 (Figure 1) (13, 14). Cells in G1 can, before commitment to
DNA replication, enter a quiescent state, called G0, when they
have reversibly withdrawn from the cell-division cycle in response
to high cell density, mitogen deprivation or some other stress situ-
ations. Alternatively, the cells may irreversibly withdraw from the
cell-cycle into terminally differentiated or senescent states. Pro-
gression through each cell-cycle phase and transition from one
phase to the next are monitored by specific checkpoints, which
maintain the correct order of events (15). If these sensors detect
aberrant or incomplete cell-cycle events (e.g., DNA damage),
checkpoint pathways carry a signal that can trigger cell-cycle arrest
until the problem is solved (16, 17). These checkpoints are gov-
erned by a tight relationship of specific cyclin-dependent kinase
(CDK), and their associated inhibitor partners of the Cip/Kip
family proteins (p21, p27, p57), which can reversibly halt cell-
cycle progression (Figure 1) (18). In addition, different protein
kinases are specific to DNA damage, like ataxia-telangiectasia-
mutated (ATM), ataxia, and rad3 related (ATR). These kinases
phosphorylate p53 in response to DNA damage, resulting in p21
blocking the cell-cycle, at least at the G1/S checkpoint (19). Fail-
ure of the checkpoints to arrest the cell-cycle may result in genetic
instability, contributing to uncontrolled proliferation implicated
in cancer development and viral replication. Mitogens release
the brakes of cell-cycle progression by stimulating G1/S CDK
activities, which trigger the phosphorylation of retinoblastoma
tumor suppressor gene product (pRb) proteins, leading to dis-
ruption of their interaction with the E2F family of transcription
factors, which play a crucial role in the control of the cell-cycle
(Figure 1) (20).
It was shown that NK cells have the ability to bind target cells
in mitosis and to attack pathogenic cells in mitosis more effec-
tively than the same cells in other stages of the cell-cycle. Thus,
cells in mitosis warrant and undergo heightened surveillance, a
novel strategy for immunologic assessment of danger (21). For
example, the cellular ligands of NKp30 (NKp30L) and NKp44
(NKp44L) were cell-cycle regulated; in the presence of colchicine
or nocodazole their expression is specifically reduced in target
cells arrest in G2/M phase, suggesting their downregulation dur-
ing mitosis (22). Similarly, stress signals cause surface expression
of NKG2D ligands (NKG2D-L) via sensors of DNA damage, like
ATM/ATR kinases, triggering signaling cascade, which leads to
cell-cycle arrest (Figure 1). (5).
Frontiers in Immunology | NK Cell Biology October 2013 | Volume 4 | Article 325 | 2
Baychelier and Vieillard NK cells and cell-cycle
RELEVANCE OF CELL-CYCLE DYSFUNCTIONS TO TRIGGER NK
LYSIS
IN CANCERS
A tight connection between the cell-cycle and cancer is obvious,
because cell-cycle machinery controls cell proliferation, and in
stark contrast to normal cells, which only divide a delimited num-
ber of times before they enter in growth arrest, whereas, cancer cells
never cease to proliferate. It appears that tumor suppressor gene
mutations are highly likely to promote, and may even be required
for, a large number of spontaneous and hereditary forms of can-
cer. Loss of function of the tumor suppressor gene product pRb,
for example, would be predicted to liberate E2F transcriptional
activators without requiring phosphorylation and thus bypass a
normal negative regulation controlling entry into the cycle. E2F
is expressed in response to growth factor stimulation and onco-
genic stress and induce transcription of target genes involved in
cell-cycle progression and DNA replication. As a result of its crit-
ical role in proliferation, the regulatory pathway for E2F is one of
the most deregulated pathways in cancer (23). Recently, Raulet’s
group have demonstrated in mice that expression of retinoic acid
early inducible gene 1 (Rae-1), an NKG2D-L, in cancer cell lines
and proliferating normal cells is coupled to the cell-cycle regu-
lation Thus, Rae-1 is directly transcriptionally activated by E2F
family transcription factors, which control the G1/S transition,
and then play a central role in the cell-cycle entry (24). Liu et al.
(25) have shown that upregulation of Rae-1 in mouse and ULBP-1
in human are dependent of the Ras pathway; an over-expression of
the constitutively active HRasV12 mutant, which accelerates cell-
cycle progression, seems sufficient to induce NKG2D-L expression
and then to increase sensitivity of cells to NK-cell-mediated cyto-
toxicity (Figure 1). It is however important to note the conflicting
roles of NKG2D and its ligands in cancer, which can promote the
destruction of malignant cells or alternatively can be exploited for
immune evasion (26).
In addition to regulating cell-cycle progression, E2F exerts a
role in the DNA damage response by inducing target genes that
function in DNA repair and recombination and DNA damage
checkpoints. E2F is directly phosphorylated by ATM and ATR
protein kinases that led to elevated mRNA expression of certain
NKG2D-L (27–29). Knockdown studies established that constitu-
tive ATM or ATR activation has an important role in maintaining
constitutive ligand expression, and then to mobilize NK cells
against the tumor (30). These studies indicated that NKG2D-L
expression on tumor cells is mediated in part by an activated
DNA damage response. On another hand, it is well established
that the ATM/ATR pathway activates p53 (Figure 1). The tumor
suppressor protein p53 is a sequence-specific DNA-binding pro-
tein that is able to induce either arrest or apoptosis at the cell-cycle
checkpoints. Consistent with a prominent role as a tumor suppres-
sor, p53 is mutated or deleted in approximately 50% of cancers,
and in the remaining tumors, p53 function is frequently impaired
(31). The deletion of p53 in various tumor cell lines indicated that
p53 is certainly not essential for ligand expression, although p53
can induce certain ULPBs (5, 32). By using ChIP and luciferase
reporter assays, they show that ULBP-1 and -2 are direct p53
target genes. Indeed, targeting of p53 by small molecular com-
pounds, like RITA and Nutlin-3, up-regulated ULBP2 expression
in sarcoma but not in carcinoma cell lines (33, 34). This could
be explained by cell type-specific DNA methylation or histone
deacetylation of the ULBP-1 or -2 promoters, and then their acces-
sibility to transcription factors, such as p53. In line with these data,
Fiegler et al. (35) have recently shown that B7-H6 expression is
downregulated in various tumor cell lines upon treatment with
histone deacetylase (HDAC) inhibitors or after siRNA-mediated
knockdown of HDAC-2 or -3. Notably, the downregulation of B7-
H6 on tumor cells by HDACi reduces NKp30-dependent effector
functions of NK cells. Thus, in this context, it would be interest-
ing to therapeutically evaluate different drug combinations, which
induce cell-cycle arrest, including DNA damage-inducing drugs
and HDAC activators to modulate ligand’s expression of activating
NK receptors.
IN VIRAL INFECTIONS
Many cellular pathways are activated early on upon viral infection
to achieve a state of survival and increased cellular proliferation for
optimal replication and production of progeny virus. The induc-
tion of cell-cycle checkpoints and activation of the ATM/ATR
dependent pathway have been reported to accompany infection
by a number of different viruses (36).
Human immunodeficiency virus 1 is a prototypic example to
study the implication of the cell-cycle in the control of the NK
pathway. Indeed, several groups have demonstrated that during
infection, ligands of activating receptors are significantly modu-
lated, consistently to the NK lysis susceptibility (9, 37). In parallel,
HIV-1 has developed numerous strategies to evade the activation
of NK cells and have influenced the evolution of NK cell receptors
and their ligands (38). During HIV-1 infection, DNA damage sen-
sor ATR but not ATM is phosphorylated and activated by the viral
protein Vpr (39). One of the benefits of ATR’s induction for HIV-1
is to induce G2 arrest (Figure 1) (40). This is associated with Vpr
binding to damaged DNA-binding protein I (DCAF1), a substrate
recognition subunit for an E3 ubiquitin ligase complex (41). ATR’s
phosphorylation through Vpr not only results in G2 arrest, but also
leads to the expression of ULBP-1 and -2, but not ULBP-3-6, or
MIC-A and -B (42). The specificity of NKG2D-L expression may
be due to ATR’s influence on the specificity protein (SP)1 and SP3
transcription factors resulting in ULBP-1 or -2 transcription (43).
Concomitantly, to facilitate viral persistence, Nef protein delays
the progression of CD4+ T cells through the G1/S phase check-
point control of the cell-cycle, involving an upregulation of p21
and p27 CDK inhibitors and the downregulation of cyclin D1
and cyclin A that promotes immune evasion and cell survival
(44). Nef is also implicated in the down modulation of NKG2D-L
(28), and NKp44L (45). Thus, the regulation of ligands for acti-
vating NK receptors expression by Vpr, Nef, and possibly other
viral proteins might have different impacts on NK cell recogni-
tion of HIV-infected CD4+ T cells. To date, direct implication
of the cell-cycle in this phenomenon remains unknown, how-
ever, Madrid and Ganem (46) recently showed that during lytic
Kaposi’s sarcoma-associated herpesvirus (KSHV) infection, the
subcellular localization of NKp44L changes; its expression on the
cell surface decreases, as we and others have previously shown in
HIV-1-infected CD4+ T cells (45). More intriguingly, they showed
the total cellular NKp44L level did not change: it was instead
mislocalized, concentrated in the nucleus. Intriguingly, KSHV is
known to encode a viral cycle, denoted K-cyclin, extraordinary by
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its ability to mimic cellular components of the cell-cycle and play
with him. Understanding the role of the virally encoded cyclin
on the ligand’s expression represents an exciting problem for the
future.
IN CELL-TO-CELL CROSS-TALKS
In addition to their role in providing antitumor and antiviral
immunity, NK cells are also able to regulate the adaptive immune
response by secreting different cytokines and chemokines (2). Sev-
eral studies have also provided evidence of cognate cell–cell inter-
actions between NK and other immune cells. Although, expression
of ligands for activating NK receptors was thought to be mostly
restricted to transformed-, infected-, and/or stressed-cells, experi-
mental evidences report that certain ligands can be also expressed
in normal situations, on bone-marrow cells, dendritic cells, and B
or T lymphocytes, possibly to regulate certain cellular responses
(28, 47, 48). The implication of activating receptors expressed by
NK cells in the direct elimination of T cells remains still elusive,
although they have been recently focus of intense research (49).
DNAM-1-L and NKG2D-L were mainly expressed on T cells
that had gone through at least one mitosis (28, 50). However, the
expression of NKG2D-L on activated CD4+ and CD8+ T cells,
in response to super-antigens, alloantigens or to a specific anti-
genic peptides, is variable, depending on the donors, but also on
the time-stimulation of T cells and the experimental settings (28).
Other and us have also reported this variability of cell-surface
expression, for ligands of NCRs and NKG2D in various pathologic
situations (22, 45). The expression and function of PVR, a ligand of
DNAM-1, another activating NK receptor, was also investigated on
T cells in response to super-antigen stimulations (50). Its expres-
sion is almost exclusively confined to cells that are in the S or G2/M
phases of the cell-cycle and that have undergone at least one divi-
sion as measured by the loss of CFSE intensity, a powerful tool to
monitor lymphocyte proliferation and to quantify cell-division. In
fact, the induction of PVR partially depends on ATM/ATR kinases
pathway on activated T lymphocytes in a ROS-dependent man-
ner. This could participate in the NK-cell-mediated recognition
and lysis of proliferating T, by a specific PVR:DNAM-1 cross-talk.
Conversely, oxidative stress has been previously found to induce
several NKG2D-L, but not PVR (51). These findings highlight the
complexity of the molecular mechanisms leading to the induction
of different ligands for distinct NK-activating receptors, and fur-
ther support the notion that they may involve common or distinct
pathways, depending on the form of stress, the type of ligand, and
the cellular context.
Thus, we could envisage that the expression of ligands for
activating receptors on proliferating T lymphocytes is a possi-
ble mechanism used by NK cells to restrict the expansion of
activated/proliferating T cells. In line with these data, the Swan-
borg’s group has recently shown that NK cells induce a reversible
p21-mediated G0/G1 cell-cycle arrest of activated T cells, both in
a contact-dependent, and an antigen non-specific manner (52).
p21 has been shown to prevent cell-cycle progression by several
mechanisms, including blocking formation of active cyclin-CDK
complexes, and inhibiting DNA replication through proliferat-
ing cell nuclear Antigens (PCNA), which is commonly over-
expressed in cancer cells, and contributes to cellular prolifer-
ation and transformation (Figure 1). Interestingly, PCNA was
recently described as an unexpected inhibitory ligand for the
NCR NKp44; an over-expression of PCNA was found to inhibit
NK cell cytotoxicity in an NKp44-dependent manner, revealing
a putative novel mechanism for pathologic cells to evade NK
attack (53, 54), closed to the numerous mechanisms developed
by tumor and infected cells to counteract their sensitivity to
NK cells (55).
CONCLUSION
As shown during this last decade, ligands for activating NK recep-
tors exhibit distinct specializations in function of different stress
situations, providing a complex warning system that relays various
danger signals through the NK system. Uncovering the molecular
mechanism that drives expression of each of these ligands remains
an active area of research in the field. The potential linkage of
these ligands to the cell-cycle control provides a new framework
for future investigations designed to elucidate how their expression
participates both in the immune homeostasis and disease control.
However, current data suggest that for the cell-surface expressions
of ligands; cell-cycle entry might be necessary but certainly not
sufficient in most cases. Thus, it is tempting to speculate that com-
pounds targeting the cell-cycle could also modulate the level of
ligand’s expression. This could serve for the design of new agents
to specifically control malignant cell proliferation or infections.
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